Basis of Presentation and Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Schedule of customers representing 10% or more of revenues

The following table sets forth customers who represented 10% or more of our total revenues for the three months ended March 31, 2017 and 2016:



	Three Months Ended March 31,
	2017		2016
AmerisourceBergen Drug Corporation	22	%	24	%
McKesson Corporation	14	%	<10	%

Schedule of customers representing greater than 10% of accounts receivable balances

Customers which represented greater than 10% of our accounts receivable balance as of March 31, 2017 and December 31, 2016 were as follows:



	March 31, 2017		December 31, 2016
AmerisourceBergen Drug Corporation	31	%	13	%
McKesson Corporation	21	%	32	%

Analysis of U.S. product sales allowances and accruals

Our product sales, which primarily represented revenues from Makena and Feraheme for the three months ended March 31, 2017 and 2016, were offset by provisions for allowances and accruals as follows (in thousands):



	Three Months Ended March 31,
	2017		2016
Gross product sales	$	206,724	$	152,192
Provision for product sales allowances and accruals:
Contractual adjustments	69,829		45,581
Governmental rebates	24,378		17,047
Total	94,207		62,628
Product sales, net	$	112,517	$	89,564